Skip to main content

Greenberg Traurig Adds Former Teva Pharma Counsel to its Expanding Philadelphia Office

PHILADELPHIA – July 16, 2018 – Continuing the steady and strategic expansion of its litigation team, Greenberg Traurig, LLP has added Brian Rubenstein as a shareholder in its Philadelphia office. Rubenstein comes to the firm with a wealth of experience, joining from Teva Pharmaceuticals, where he was an associate general counsel.  

“We are thrilled to have Brian join us,” said Curtis B. Toll, managing shareholder for the Philadelphia office. “In strategically growing our Litigation Practice here, we want to deliver the most meaningful counsel and highest value to our clients. Brian’s deep knowledge of the inner workings of pharmaceutical companies and product liability issues in state and federal courts, as well as the corporate perspective he brings from his tenure at Teva, make him a remarkable asset for the firm and its clients.” 

Rubenstein has a broad range of experience in defense of complex, large-scale matters, notably at Teva, where he played a critical role in the landmark 2011 U.S. Supreme Court decision, Pliva v. Mensing. Pliva created a sea change in the industry by ruling that generic pharmaceutical manufacturers cannot be sued under state law for failing to warn customers about associated product risks.  

“With some sizable wins and great opportunities under my belt, I was looking at how I could grow further and become even stronger as an attorney,” Rubenstein said. “After working in an arena like the one I came from, it had to be a special place, one with a global reputation for skill, quality, and innovation.  

“Greenberg Traurig was the perfect fit. And being part of what is happening at GT Philadelphia sealed the deal for me. I’m excited to bring all that I have learned to this practice and this firm.” 

An experienced litigator, Rubenstein has handled a wide range of large-scale, complex business disputes – as well as investigating and coordinating responses to government subpoenas and inquiries from the U.S. Food and Drug Administration and Federal Trade Commission.  

A graduate of Wharton, Rubenstein earned his J.D. from Loyola University Chicago School of Law, where he also served on the Loyola University Chicago Law Journal. Admitted in both Pennsylvania and New York, he also has clerked for U.S. Circuit Judge William J. Bauer.  

“For many years while Brian was at Teva, my team and I worked closely with him as we defended significant matters and prepared cases for trial. Now we will have the benefit of his strategic insight on our team directly, and that will yield dividends for us and more importantly, our clients,”  said Lori G. Cohen, co-chair of the firm’s Global Litigation Practice, chair of the Pharmaceutical, Medical Device & Health Care Litigation Practice, and chair of the firm's Trial Practice Group. “At Teva, he proved to be an accomplished litigator and leader, and his addition demonstrates our on-going commitment to identify the best talent to serve our clients in these critical practice areas. From his educational training to his years of excellent, even ground-breaking practice, Brian represents the ideal mind that we want for GT.”  

“Even amid 600 attorneys firmwide in the Global Litigation Practice, Brian is expected to be a standout,” said Jeff E. Scott, co-chair of the firm’s Global Litigation Practice.  

“Brian is a terrific addition and his experience in litigating complex disputes, as well as antitrust and regulatory issues, further enhances our team of high-stakes litigators who are available to assist our clients, both locally and nationwide. In a very challenging industry, we’re proud to have this level of quality and experience to offer.” 

About Greenberg Traurig’s Litigation PracticeGreenberg Traurig’s Litigation Practice includes a team of more than 600 attorneys. The firm’s trial lawyers regularly appear in state and federal courts throughout the country, as well as in appellate courts and before international arbitration panels. They work closely with in-house counsel to develop a strategy that best fits a litigation cost and proficiency model appropriate to the client’s unique needs goals. 

About Greenberg Traurig’s Pharmaceutical, Medical Device & Health Care Litigation PracticeThe Pharmaceutical, Medical Device & Health Care Litigation Practice is an integral part of the firm’s 600-plus member national Litigation Practice. The team is nationally recognized for its dynamic courtroom presence, responsiveness to clients, and deep subject matter knowledge. Recent recognitions include national rankings for 2017 “Products Liability & Mass Torts” from Chambers USA Guide; national rankings for 2017 “Practice Liability & Mass Torts Defense: Pharmaceuticals and Medical Devices” from The Legal 500 United States; and being named the Products Liability/Mass Torts Litigation Department of the Year by the Daily Report in 2013, 2015 – 2017. In addition, Greenberg Traurig is recognized as a "Product Liability Litigation Standout" in the BTI Litigation Outlook 2018 published by BTI Consulting Group. 

About Greenberg Traurig: Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2017 Am Law Global 100. Web: Twitter: @GT_Law.